FDA Approves New Potency Assay for Ryoncil, Boosting Quality Control
MESO sits 20% above its 52-week low of $13.05 on elevated volume (1.9× avg).
Summary
Mesoblast received FDA approval to implement a new potency assay for Ryoncil, its commercial cell therapy. This enhances quality control and manufacturing consistency, potentially supporting expanded use and regulatory confidence. The approval follows the 6-K filed earlier today and builds on strong FY2026 Ryoncil revenue of $115.2M. Watch for updates on manufacturing scale-up and any impact on supply capacity.
At the time of this announcement, MESO was trading at $15.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $13.05 to $21.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.